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Persistence of immunity to hepatitis B vaccine as  
infants, 17 years earlier 
 
 
Abstract 
Background: In Iran since 1992, hepatitis B vaccination was a part of the national 
vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis 
B. The aim of this study was to evaluate the long – term persistence of immunity. 
Methods: This cross-sectional analytical study was conducted on children and adolescents 
aged between 6-18 years in Birjand, who received a three – dose hepatitis B vaccination in 
accordance with the national immunization program. No students were infected with 
hepatitis B. Antibody titer higher than10 IU/L was considered positive. 
Results: A total of 530 patients (307 boys and 223 girls) were recruited for the study of 
which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean 
(GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4% 
of the boys and 59.6% of the girls. A significant difference in antibody titers was observed 
in terms of gender and according to the time elapsed since the last vaccination. Antibody 
titer in children older  than 13 years had passed since their last vaccination and was 
significantly less than those children younger than thirteen years old had passed since their 
vaccination logistic regression analysis showed that the only predictive factor of anti-HBS 
low titer (<10 IU/L) is elapsed time of vaccination. 
Conclusions: Based on results of this study, hepatitis B vaccine has created a good level of 
protection in 44% of the adolescents after 17 years. 
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Hepatitis B infection is a major health problem worldwide, more particularly in 
Asia. It can with different degrees (1). lead to serious complications such as cirrhosis and 
hepatocellular carcinoma (2). According to the World Health Organization (WHO) two 
million people are infected with hepatitis B virus worldwide more than 350 million people 
are chronically infected, and approximately two million people die of hepatitis B-related 
complications annually (3). The prevalence of hepatitis associated with HIV varies across 
the globe. Positive HBS antigen prevalence is less than 2% in the general population of the 
developed countries, such as Western Europe and North America. The rate is 2-8% in 
Asian countries and more than 8% in Africa and East Asia (4). In the city of Birjand in 
eastern Iran, incidence of HBV has been reported 1.3%, which is by far lower than the rest 
of the country and other Asian countries (5, 6). but chronic hepatitis B is the most common 
cause of hepatocellular carcinoma and liver failure (7). One of the main ways to control 
hepatitis B infection is the widespread use of hepatitis B vaccine. Since 1991, WHO 
offered a vaccination program against HBV in all countries, universal immunization 
program (6, 7). Hepatitis B vaccination has been part of the national immunization 
program in Iran from 1992. Initially, the vaccination program against hepatitis B for 
neonates was set for 0-1.5-9 months; however, it changed to 0-2-6 months from 2005 (8). 
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The immunity persistence of childhood vaccination of 
hepatitis B is one of the debatable issues. Immunity period of 
hepatitis B full vaccination depends on antibody titer created 
and its stable time length to a higher concentration of 
antibody titer of immunogenicity in the serum (7, 8). In a 
study in 2004 in Iran, antibody titer of children was 
examined 10 years after the infant’s vaccination. The results 
showed that 58% of children had protective antibody titer 
(10 IU/L) after ten years (3). In Iran, information about the 
long-term performance of the vaccine is limited and 
incomplete. Since hepatitis B vaccination is effective in its 
epidemiology, this study was conducted to evaluate its long 
term persistence of immunity. 
 
 
Methods 
This cross-sectional analytical study was conducted 
from 2015 (September - December) on children residing  in 
Birjand aged between 6 and 18 years who received the three-
dose hepatitis B vaccine in accordance with the national 
immunization program. The sample was selected by 
multistage cluster sampling method. First, the city of Birjand 
was divided into four districts based on geographical 
situation. A list of school districts in each locality namely: 
elementary, middle and high schools was obtained from the 
Office of Education of Birjand. Two girls schools and two 
boys schools were selected randomly from the list of schools 
(in total, 24 girls’ and 24 boys’ schools).  
In each school in each grade, one class was selected 
randomly according to the population of each class, and 
several students from each class were systematically selected 
at random. A sample size of 534 people was estimated based 
on the formula. After selecting the sample, a written consent 
was obtained from parents for inclusion, and a self-made 
questionnaire was completed for the students based on the 
project objectives.  
The questionnaire, whose content validity was approved 
by five faculty members, consisted of information on 
demographics and vaccination status of specific diseases 
including hepatitis B. The vaccination basis was health 
vaccination cards of students in their school files. Inclusion 
criteria were all children who received three doses of HBV 
vaccine. Children who had received immunoglobulin, blood 
products, and other immunodeficiency drugs in the past three 
months or incomplete hepatitis B immunization were 
excluded.  
Serologic Test: After permission was obtained and 
coordination made with the Office of Education, 3 ml blood 
samples were taken and stored in serum isolation at -20 °C 
until the required tests were performed. After collecting 
samples, serum titer of hepatitis B surface antibody (anti-
HBS) (bioELISA anti HBS Bio kit, Barcelona, Spain), 
hepatitis B surface antigen (HBS Ag) (Enzygnost HBS 
Ag5.o, Dade Behring Inc. Newark USA), hepatitis B core 
antibody (anti- HBC) (bio ELISA anti HBC, Bio kit, 
Barcelona, Spain) were conducted using ELISA method. At 
this stage, those with positive HBS Ag or anti-HBC were 
excluded (4 individuals were: HBS-Ag positive or HBS –Ab 
positive then). Finally, 530 patients were enrolled. All these 
people had received Engerix B vaccine made in Cuba or Iran 
with 10 microgram dose within 0-1.5-9 or 0-1-6 months. 
Antibody titer less than 10 Iu/L was considered negative and 
10 IU/L was considered safe (according to the mentioned 
catalog kit). 
Statistical Analysis: The data collected were analyzed in 
SPSS-16 software using Mann-Whitney, Kruskal-Wallis 
(given the non-normal distribution of antibody titer), chi-
square, Pearson correlation coefficient, and logistic 
regression. The significant level was set at α=0.05. 
 
 
Results 
This study included 530 children and adolescents aged 
between 8 and 18 years (307 males and 223 females) with 
the mean age of 13.1±2.3 years. All subjects were negative 
HBS Ag and negative anti-HBC. Demographic and 
epidemiological data of the subjects are displayed in (table 
1). From these, 223 (44%) had positive antibody titer (≥10 
IU/L). The geometric concentration mean (GMCs) of 
antibody in subjects was 64.9±34.2 (with a minimum of zero 
and a maximum of 250). The mean BMI in our study was 
22.3±2.4 (with a minimum of 18.85 and a maximum of 
37.17). In 40.4% of the boys and 59.6% of the girls, HBS 
antibody titer was positive. A significant difference in 
antibody titers was observed in terms of gender and elapsed 
time after vaccination. 
Antibody titer was significantly less in children with 
over 13 years than those with less than 13 years from their 
last vaccination. While the mean antibody titer was higher in 
girls than boys, the difference was not statistically significant 
(table 2). A negative, significant correlation was found 
between antibody titer and age. Finally, to determine factors 
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associated with antibody titer less than 10 IU/L, logistic 
regression analysis showed that the only predictive factor is 
elapsed time from the last vaccination (table 3). 
 
Table 1. Characteristics of students stratified by anti-
HBS titer 
HBS-Ab 
 
>10 
N(%) 
<10 
N(%) 
Chi-square test 
Gender 
Male 
female 
 
124(40.4) 
109(48.9) 
 
183(59.6) 
114(51.1) 
P=0.05 
Education 
Illiterate 
Primary 
Secondary and Highschool 
graduate 
College 
 
8(53.3) 
42(53.2) 
25(41.7) 
45(44.1) 
32(48.5) 
 
7(46.7) 
37(46.8) 
35(58.3) 
57(55.9) 
34(51.5) 
P=0.64  
Mother occupation 
Housekeeper 
Staff 
Self-employed 
 
129(48.3) 
16(41) 
7(46.7) 
 
138(51.7) 
23(59) 
8 (53.3) 
P=0.69  
Vaccine status 
vaccinated≤13years 
vaccinated>13years 
 
152(49.5) 
84(36.7) 
 
155(50.5) 
145(63.3) 
P=0.003 
 
Table 2. Comparison of GMCs by gender and vaccine 
status in students 
 Frequency Mean±SD 
Mann-
whitney test 
Gender 
Male 
Female 
 
307 
223 
 
61.4±31.1 
69.4 38.5 
P=0.06 
Vaccine status 
vaccinated≤13years 
vaccinated>13years 
 
307 
229 
 
71.1±40.52 
53.8±25.32 
p<0.001 
GMCs: Geometric Concentration Mean 
 
Table 3. Logistic regression analysis of variable related to 
variation of anti-HBS<10 IU/L 
Parameter Odds ratio 95% CI P-value 
Gender: female vs. 
male 
0.71 0.501-1.003 0.052 
Vaccine status:  
vaccinated≤13years 
vaccinated>13years 
 
1 
1.69 
1.19-2.4 0.023 
95% CI: Confidence Interval 
Discussion 
This seroepidemiologic retrospective study was 
performed to evaluate the immunity of children and 
adolescents who received vaccination during the neonatal 
period. According to the literature, this seems to be the first 
study to assess the immunity persistence in children and 
adolescents up to 17 years from the time of vaccination. 
Vaccination of Iranian infants with a dose of 10 micrograms 
of recombinant hepatitis B vaccine in accordance with the 0-
1.5-9 months program of 1992 was included in the national 
immunization program. Since 1998, recombinant Engerix-B 
vaccine manufactured by SmithKline, Belgium has been 
imported and used. However, long after the recombinant 
Herbert Biovac-HP vaccine (made in Cuba) with the same 
dose was used. From 2005 to present, the Iranian 
recombinant hepatitis B vaccine with a dose of 10 
micrograms is used in accordance with the 0-2-6 table of the 
national immunization program (7, 8). 
 The criterion for immunity in vaccination with hepatitis 
B vaccine is concentration of anti-HBS antibody in the 
serum. If the concentration of the produced antibody is 
higher, the achieved immunity will be greater (9). Immunity 
duration achieved by a whole series of hepatitis B 
vaccination depends on antibody titer and stability duration 
of serum titer (10, 11). Based on this study, 56% of the 
subjects over 17 years after vaccination were reported to 
have lost antibodies of the vaccine. Moreover, the average 
concentration of antibodies underwent a significant 
reduction. If the findings of this study are compared with 
previous studies in Iran, it seems that similar results were 
obtained, and about half of the children lost the acquired 
immunity by HBV vaccination in less than 15 years (9, 11). 
In various studies carried out on diverse and high-risk 
populations years after HBV vaccination, 15-50% of the 
vaccinated children have lost measurable anti-HBS titer 5-15 
years after vaccination, and average concentrations of 
antibody also reduced significantly (12, 13).  
In some investigations, 5 years after vaccination, 
children born from mothers who are chronic carriers of 
hepatitis B, 16% of immunized children lost the acquired 
immunity (3). In Seto and Shih’s study, 6-7 years after 
vaccination 43% and 81% of immunized children, had lost 
their immunity (12, 14).  The results of all above studies 
suggested that antibody titers decreased over time. In this 
study, 44% of subjects had antibody titer more than 10 IU/L 
(which had been accepted as a protective titer) and 15% had 
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antibody titer less than 10 IU/L (1-9 IU/L). It was found that 
the persistence of antibody titer exists after 13 years, which 
is consistent with the findings in some studis (15-17). There 
is scientific evidence that people whose antibody titer 
reduces to less than 10 IU / L or their antibody titer becomes 
negative, are still protected against hepatitis B, because the 
immunologic memory to HBS Ag continues (13, 18). Even 
in these people, there is a guarantee to experience a sharp 
increase in antibody titer in the exposure of hepatitis B virus 
(19-22). Furthermore, based on some studies, it has been 
proven that people with antibody titer less than 50 IU/L after 
hepatitis B vaccination, may have hepatitis B. Accordingly, 
in some European countries, the minimum protective titer of 
100 IU/L is considered (16, 23).  
The duration of immunity persistence after hepatitis B 
vaccination and its role in immunity is still controversial. In 
fact, there is no scientific evidence that immunity is only 
based on the anti-HBS amount. Therefore, based on the 
WHO recommendation, people with antibody less than 10 
IU/L are considered immunized due to the strong role of the 
response of cellular immunity against hepatitis B (16, 24). 
There were limitations in this study, because this was a 
retrospective seroepidemiology study. There was a lack of 
sufficient information in retrospective studies because these 
studies are usually inevitable. One of the important 
limitations of this study is the lack of information about the 
original antibody titer after vaccination in the neonatal 
period. So it is not clear that anyone who has antibody titre 
below 10 IU/L whether having primary and secondary 
decreased antibody titer happens over time. 
Today, according to some studies, one of the reasons 
associated with lower anti-HBS titers is introduced as a 
routine immunization for infants, and they believed that 
vaccination during adolescence contributes significantly to 
hepatitis B vaccination associated with this progressive 
evolution of the immune system during childhood. Immune 
system in infants with poor performance of T cells, low 
interaction between T and B cells and immunoglobulin 
limitation cause reduced antibody response (25, 26). These 
observations cause strategy of hepatitis B vaccination time to 
be revised for a better and more effective response to the 
prescribed vaccine. In addition, another limitation of this 
design is the lack of information about the status of mothers 
in term of hepatitis B immunity or catching. The presence of 
anti-HBS in serum of some mothers may affect response to 
hepatitis B vaccine in newborns and reduce the immunogenicity 
of hepatitis B at birth (4). In spite of that, the, results of one 
study have shown that 22% of babies born of mothers 
infected with HBV do not have the ability to produce anti-
HBS after three doses of hepatitis B vaccine, and in majority 
of these individuals HBV-DNA was observed in their 
peripheral blood mononuclear cells (PBMC). Although there 
is not HBV-DNA in PBMC of infants who were born of 
infected mothers, they had immunity antibody response to 
the vaccine (8, 27). One important factor that affects immune 
response is body mass index (BMI) in which unfortunately 
in this study, the calculated BMI is associated with the time 
of investigation of antibody titers during the study period. 
In conclusion, Hepatitis B vaccine has a very good 
performance to prevent hepatitis B and has created a good 
level of protection in 44% of the adolescents after 17 years. 
It is suggested to conduct a study on virus – exposed youth 
to evaluate the effectiveness and immunity continuity of 
hepatitis B virus vaccination. 
 
 
Acknowledgments 
We would like to thank the Office of Education of 
Birjand, Research Center of Birjand University of Medical 
Sciences who collaborated with this project. 
 
Funding: This study was supported by the infectious 
Diseases Research Center of Birjand University of Medical 
Sciences (2015) IR-BUMS.REC.1394.397. 94/12/22 
Conflict of interests: None declared. 
 
References 
1. Heidari M, Bayani M, Bijani A, Hasanjani Roushan MR. 
Factors influencing therapeutic response to pegylated 
interferon plus ribavirin in the different genotypes of 
chronic hepatitis C. Caspian J Intern Med 2014; 5: 219-22. 
2. Shafaei S, Amiri SS, Hajiahmadi M, Sadeghi-Haddad-
Zavareh M, Bayani M. Histological grading and staging 
of liver and its relation to viral loads in chronic anti-HBe 
positive hepatitis. Caspian J Intern Med 2013; 4: 681-5. 
3. Saffar M, Rezai M. Long-term antibody response and 
immunologic memory in children immunized with hepatitis B 
vaccine at birth. Koomesh  J 2004; 5: 63-72. [in Persian] 
4. Coppola N, Corvino AR, De Pascalis S, et al. The long-
term immunogenicity of recombinant hepatitis B virus 
(HBV) vaccine: contribution of universal HBV 
vaccination in Italy. BMC Infect Dis 2015; 15: 149. 
 Caspian J Intern Med 2018; 9(2): 184-188   
188                               Azarkar, et al. 
5. Ziaee M, Sharifzade GR, Azarkar G, et al. 
seroprevalence and risk factors of hepatits B virus 
infection birjandiran: A population- based study. 6th 
Tehran hepatitis Conference. May 2015.  Available at: 
http://6.thc.ir/ wpcontent/ uploads/2015/06/Booklet.pdf 
6. Soleimani Amiri S, Soleimani Amiri MJ, Hasanjani 
Roushan MR. Possible sources for transmission of 
Hepatitis B Virus Infection in 80 Children in Babol, 
North of Iran. Caspian J Intern Med 2010; 1: 50-2. 
7. Biazar T, Yahyapour Y, Hasanjani Roushan MR, et al. 
Relationship between hepatitis B DNA viral load in the 
liver and its histology in patients with chronic hepatitis 
B. Caspian J Intern Med 2015; 6: 209. 
8. Jafarzadeh A. The factors influencing the immune 
response to hepatitis b vaccine and persistance of the 
protection.  J Rafsanjan Univ Med Sci Health Serv 2002; 
1: Available at: http://www. sid.ir/En/Journal/ View 
Paper.aspx?ID=34087 
9. Zahraei SM, Marandi A, Sadrizadeh B, et al. Role of 
National Immunization Technical Advisory Group on 
improvement of immunization programmes in the 
Islamic Republic of Iran. Vaccine 2010; 28: A35-8. 
10. Soleimany Amiri S, Shafaee S, Hasanjani Roushan MR, 
Baiani M, Hajiahmadi M. Evaluation of the need for 
treatment on 72 subjects with anti-HBe positive chronic 
hepatitis B. Caspian J Intern Med 2012; 3: 519-22. 
11. Janbakhsh A, Mansouri F, Vaziri S, et al. Effect of 
selenium on immune response against hepatitis B vaccine 
with accelerated method in insulin-dependent diabetes 
mellitus patients. Caspian J Intern Med 2013; 4: 603-6. 
12. Seto D, West DJ, Ioli VA. Persistence of antibody and 
immunologic memory in children immunized with 
hepatitis B vaccine at birth. Pediatr Infect Dis J 2002; 21: 
793-5. 
13. Thio C, Hawkins C. Hepatitis B virus and hepatitis delta 
virus. In: Mandell GL, Bennet JE, Dolin R. Principle and 
practice of infectious disease. 7th ed. Philadelphia: 
Elsevier-Churcill Livingstone 2015; pp: 1834-36.  
14. Shih HH, Chang MH, Hsu HY, et al. Long term immune 
response of universal hepatitis B vaccination in infancy: 
a community-based study in Taiwan. Pediatr Infect Dis J 
1999; 18: 427-32. 
15. Williams IT, Goldstein ST, Tufa J, et al. Long term 
antibody response to hepatitis B vaccination beginning at 
birth and to subsequent booster vaccination. Pediatr 
Infect Dis J 2003; 22: 157-63. 
16. Grosso G, Mistretta A, Marventano S, et al. Long-term 
persistence of seroprotection by hepatitis B vaccination 
in healthcare workers of southern Italy. Hepatitis Mon 
2012; 12: e6025. 
17. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody 
levels and protection after hepatitis B vaccination: results 
of a 15-year follow-up. Ann  Intern Med 2005; 142: 333-41. 
18. Spada E, Romanò L, Tosti M, et al. Hepatitis B immunity 
in teenagers vaccinated as infants: an Italian 17‐year 
follow‐up study. Clin Microbiol Infect 2014; 20: O680-O6. 
19. Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van 
Damme P. Immune memory and immune response in 
children from Bulgaria 5-15 years after primary hepatitis 
B vaccination. Pediatr Infect Dis J 2013; 32: 51-3. 
20. Zhu CL, Liu P, Chen T, Ni Z, et al. Presence of immune 
memory and immunity to hepatitis B virus in adults after 
neonatal hepatitis B vaccination. Vaccine 2011; 29: 
7835-41. 
21. Zanetti AR, Romanò L, Giambi C, et al. Hepatitis B 
immune memory in children primed with hexavalent 
vaccines and given monovalent booster vaccines: an 
open-label, randomised, controlled, multicentre study. 
Lancet Infect Dis 2010; 10: 755-61. 
22. Gara N, Abdalla A, Rivera E, et al. Durability of 
antibody response against hepatitis B virus in healthcare 
workers vaccinated as adults. Clin Infect Dis 2015; 60: 
505-13. 
23. Zanetti AR, Mariano A, Romanò L, et al. Long-term 
immunogenicity of hepatitis B vaccination and policy for 
booster: an Italian multicentre study. Lancet 2005; 366: 
1379-84. 
24. Gabbuti A, Romanò L, Blanc P, et al. Long-term 
immunogenicity of hepatitis B vaccination in a cohort of 
Italian healthy adolescents. Vaccine 2007; 25: 3129-32. 
25. Buffington J, Mast E.  Viral hepatitis. In: Wallace RB, 
editor. Wallace/MaxcyRosenau-last public health and 
preventive medicine. 15th ed. New York: McGraw Hill 
2007; pp: 211-28.  
26. Hofmann F, Kralj N. Criteria for successful hepatitis B 
vaccination in adults: results of a case study. Infection 
2009; 37: 266-9. 
27. Siegrist CA. Vaccination in the neonatal period and early 
infancy. Int Rev Immunol 2000; 19: 195-219. 
 
